HCV
in Corrections: Frontline or Backwater?
(continued)
Disclosures:
*Nothing to disclose
**Consultant & Speaker's
bureau: Abbott, Agouron Pharmaceuticals, BMS, Boehring-Ingelheim, Cubist,
Fujisawa, Gilead, GSK, IntraBiotics, Merck, Ortho McNeill, OrthoBiotech,
Pfizer, Roche, Schering, Trugene/Visible Genetics
*** Consultant & Speaker's
bureau: Abbott, Agouron Pharmaceuticals, Merck, Roche, Boehringer-Ingelheim
References
1. http://www.cdc.gov/ncidod/diseases/hepatitis/c_training/
edu/1/epidem-trans-4.htm
2. Thorpe LE, Ouellet LJ,
et al. Am J Epidem 2002; 155 (7): 645-653.
3. Table and figure courtesy
of Michael Wong, MD
4. Reindollar RW. Am J Med,
1999 Dec 27; 107 (6B): 100S-103S.
5. Hammett TM, Harmon P,
and Rhodes W. The Burden of Infectious Diseases Among Inmates and Releasees
from Correctional Facilities. Prepared for NCCHC-NIJ "Health of Soon-to-be-Released
Inmates" Project, June 14-15, 1999, Chicago, IL.
6. Hepatitis Control Report,
Winter 1999-2000; 4(4), 1.
7. Brown University student
Marcus Jang and HEPP staff Rebecca Nerenberg have contacted correctional
medical decision-makers in 30 states, assessing the estimated prevalence
of HCV, criteria for testing and treating HCV, the types of testing are
available, and the education inmates receive about HCV infection and transmission.
8. Satoor S, Raufman JP.
Clin Cornerstone 3 (6): 36-26, 2001.
9. MMWR 1998 Oct 16; 47
(RR19).
10. Pfister JR. CDC Consultants'
Meeting, Atlanta GA, March 5-7, 2001.
11. Bonacini, M, Puoti M.
Arch Intern Med. 2000; 160 3365-3373.
12. Bonacini, M. AIDS Reader
12 (1): 19-26, 2002.
13. See the CDC Serostatus
Approach to Fighting the Epidemic, SAFE, March 2001 HEPP News.
14. Schiff ER, Maddrey WC,
et al. Tx Reporter. Jan 2001; 7-9.
15. Manns MP, McHutchison
JG, Gordon S, et al. [abstract 552]. Hepatology 2000; 32: 297A.
16. Manns MP, McHutchison
JG, et al. Lancet 2001; 358: 958-65.
17. Peters MG, Louie K,
Terrault N. Medscape HIV/AIDS eJournal 8 (1), 2002. http://www.medscape.com/viewarticle/420681
18. Providers must contact
the Access Assurance program (1-888-437-2608) to register their patients
for the first-come, first-serve wait list for PEG-Intron supply. In a written
statement in January, Schering Plough estimated a 10-12 week wait for new
patients beginning therapy, however the manufacturer currently does not
believe anyone will have to wait the full 10-12 weeks.
19. Sherman KE, Horn P,
Rouster S, et al. Abstract 122, 9th CROI, Feb 24-28, 2002; Seattle, WA.
20. Wong JB. Am J
Med. 2000 Apr 1; 108(5): 366-373.
21. Lake-Bakaar, G.
Lancet 2002; 359 (9311): 1064.
22. http://www.cdc.gov/ncidod/diseases/hepatitis/twinrix.htm
23. 1999 USPHS/IDSA Guidelines.
MMWR 1999, 48 : 1-59.
24. http://www.cdc.gov/mmwr/PDF/RR/RR4810.pdf
25. Di Martino V, Cavallaro
L, Ezenffis J, et al. Abstract 1095, 52nd Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD); Nov 9-13, 2001; Dallas,
TX.
26. Darby SC, Ewart DW,
et al. Lancet 1997; 350: 1425-1431.
27. Benhamou Y, Bochet M,
Di et al. Hepatology 1999; 30: 1054-1058.
28. Soto B, Sanchez-Quijano
A, et al. J Hepatol 1997; 26 : 1-5.
29. Puoti M, Bonacini M
, et al. J Infect Dis 2001; 183: 134-137.
30. National Institutes
of Health Consensus Development Conference Panel Statement: Management
of Hepatitis C. Hepatology 1997; 26 (Suppl 1): 2S-10S.
31. Dieterich D, Fischl
M, Rimland D, Sepulveda G. Abstract 663-M, , 9th CROI, Feb 24-28, 2002;
Seattle, WA.
32. Benhamou Y, Di Martino
V, et al. Hepatology, 2001; 34:283-7.
33. Talal AH, Canchis PW,
Jacobson IM. Cur Gastr Rep 2002, 4:15-22.
34. Bini E, Reid M, Klinzman
D, et al. Abstract 653, 52nd AASLD;
Nov 9-13, 2001; Dallas,
TX.
35. Chung R, Andersen J,
Alston B, et al. Abstract LB15, 9th CROI, Feb 24-28, 2002; Seattle, WA.
36. Khalili M, Hoffman-Terry
M, Hassanein T, et al. Abstract 623, 52nd AASLD; Nov 9-13, 2001; Dallas,
TX.
37. Turriani FJ, Ribeiro
RM, Gilbert TL, et al. Abstract 121, 9th CROI, Feb 24-28, 2002; Seattle,
WA.
38. Perez-Olmeda M, Romedo
M, Asensi V, et al. Abstract 641, 52nd AASLD; Nov 9-13, 2001; Dallas, TX.
39. Sabin C, Dauer B, Phillips
An, et al. Abstract 639-M, 9th CROI, Feb 24-28, 2002; Seattle, WA.
40. Fuster D, Tural C, Tor
J, et al. Abstract 646-M, 9th CROI, Feb 24-28, 2002; Seattle, WA.
41. Carpenter CJ, Cooper
DA, Fischl MA, et al. JAMA 2000, January 19; 283(3): 381-391.
42. MMWR 2001 Nov 9; 50
(RR19). http://www.cdc.gov/mmwr/PDF/RR/RR5019.pdf
43. MMWR 1998 Oct 16; 47
(RR19). http://www.cdc.gov/mmwr/PDF/RR/RR4719.pdf
44. Puoti M, Bonacini M,
et al. J Infect Dis 2001; 183: 134-137.
45. Dieterich DT.
The AIDS Reader 2002; 12 (1): 22-23.
46. Garfein RS, Vlahov D,
Galai N, Doherty, MC, Nelson, KE. Am J Pub Health 1996; 86: 655-61.
47. Staples CT, Rimland
D, Dudas D. CID 1999; 29: 150-154
|
|
|
